CRVS
HEALTHCARECorvus Pharmaceuticals Inc
$15.45-0.25 (-1.59%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CRVS Today?
No stock-specific AI insight has been generated for CRVS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.38$26.95
$15.45
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS$-0.53
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding84.1M
CRVS News
21 articles- Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsightGlobeNewswire Inc.·Apr 27, 2026
- Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of DirectorsYahoo Finance·Apr 23, 2026
- Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual MeetingYahoo Finance·Apr 21, 2026
- Apple upgraded, Qualcomm downgraded: Wall Street's top analyst callsYahoo Finance·Apr 17, 2026
- Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price GainsYahoo Finance·Mar 13, 2026
- Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 13, 2026
- Corvus (CRVS) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 13, 2026
- Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Mar 13, 2026
- Corvus Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 12, 2026
- Corvus: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 12, 2026
- Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026Yahoo Finance·Mar 5, 2026
- Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026Marketbeat·Feb 27, 2026
- Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 23, 2026
- Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price SurgeYahoo Finance·Feb 17, 2026
- Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026Marketbeat·Feb 2, 2026
- Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's WhyYahoo Finance·Jan 27, 2026
- Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should KnowYahoo Finance·Jan 27, 2026
- Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a BetYahoo Finance·Jan 27, 2026
- Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% JumpYahoo Finance·Jan 27, 2026
All 21 articles loaded
Price Data
Open$15.08
Previous Close$15.70
Day High$15.62
Day Low$14.87
52 Week High$26.95
52 Week Low$3.38
52-Week Range
$3.38$26.95
$15.45
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS$-0.53
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding84.1M
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—